Vasoconstrictor responses to 5-hydroxytryptamine in the autoperfused hindquarters of spontaneously hypertensive rats.
In this work we studied the responses and receptors involved in the effects of intra-arterial 5-hydroxytryptamine (5-HT) in the in situ autoperfused hindquarters of spontaneously hypertensive rats (SHR). Intra-arterial administration of the highest doses (50-1,000 ng/kg) produced a vasoconstrictor effect that was inhibited by ritanserin (a selective 5-HT2 receptor antagonist), SB 206553 (a selective 5-HT(2B/2C) receptor antagonist) and spiperone (a nonspecific 5-HT(1/2A) receptor antagonist), and was mimicked by alpha-methyl-5-HT (a selective 5-HT2 receptor agonist) and m-CPP (a selective 5-HT2C receptor agonist), but not by the intra-arterial administration of BW 723C86, a selective 5HT2B receptor agonist. SB 206553 and spiperone inhibited alpha-methyl-5HT-induced vasoconstriction in the hindquarters of SHR. Our data suggest that the vasoconstrictor response induced by 5-HT in the autoperfused hindquarters of SHR is mainly mediated by the activation of 5-HT2A and 5-HT2C receptors.
Calama
E
E
Departamento de Fisiología y Farmacología, Facultad de Farmacia, Universidad de Salamanca, Campus Miguel de Unamuno, Salamanca, Spain.
Morán
A
A
Ortiz de Urbina
A V
AV
Martín
M L
ML
San Román
L
L
D000818:Animals; D004305:Dose-Response Relationship, Drug; D006614:Hindlimb / Q000098:blood supply / Q000187:drug effects* / Q000502:physiology; D007211:Indoles / Q000494:pharmacology; D007269:Injections, Intra-Arterial; D007275:Injections, Intravenous; D008297:Male; D010477:Perfusion; D010879:Piperazines / Q000494:pharmacology; D011224:Prazosin / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology; D051381:Rats; D011918:Rats, Inbred SHR; D017208:Rats, Wistar; D044282:Receptor, Serotonin, 5-HT1A / Q000008:administration & dosage; D044402:Receptor, Serotonin, 5-HT2A / Q000008:administration & dosage / Q000502:physiology; D044403:Receptor, Serotonin, 5-HT2B / Q000008:administration & dosage; D044405:Receptor, Serotonin, 5-HT2C / Q000008:administration & dosage / Q000502:physiology; D044348:Receptors, Serotonin, 5-HT2 / Q000008:administration & dosage; D012039:Regional Blood Flow / Q000187:drug effects / Q000502:physiology; D016713:Ritanserin / Q000494:pharmacology; D012701:Serotonin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics* / Q000494:pharmacology / Q000502:physiology; D058829:Serotonin 5-HT1 Receptor Antagonists; D058826:Serotonin 5-HT2 Receptor Agonists; D058830:Serotonin 5-HT2 Receptor Antagonists; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage / Q000493:pharmacokinetics; D013134:Spiperone / Q000494:pharmacology; D013876:Thiophenes / Q000494:pharmacology; D014661:Vasoconstriction / Q000187:drug effects* / Q000502:physiology*
C092430:1-(5-(2-thenyloxy)-1H-indol-3-yl)propan-2-amine; D007211:Indoles; D010879:Piperazines; D011725:Pyridines; D044402:Receptor, Serotonin, 5-HT2A; D044403:Receptor, Serotonin, 5-HT2B; D044405:Receptor, Serotonin, 5-HT2C; D044348:Receptors, Serotonin, 5-HT2; D058829:Serotonin 5-HT1 Receptor Antagonists; D058826:Serotonin 5-HT2 Receptor Agonists; D058830:Serotonin 5-HT2 Receptor Antagonists; D017366:Serotonin Receptor Agonists; D013876:Thiophenes; D044282:Receptor, Serotonin, 5-HT1A; D016713:Ritanserin; C042390:alpha-methylserotonin; D012701:Serotonin; D013134:Spiperone; C094868:SB 206553; C015068:1-(3-chlorophenyl)piperazine; D011224:Prazosin